Xenon Pharmaceuticals Inc.
XENE
$40.15
$1.092.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 22.52% | 2.91% | |||
| Gross Profit | -39.64% | 9.71% | |||
| SG&A Expenses | 1.08% | 5.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.44% | 3.56% | |||
| Operating Income | -29.55% | 6.12% | |||
| Income Before Tax | -32.05% | 7.07% | |||
| Income Tax Expenses | -246.60% | 111.10% | |||
| Earnings from Continuing Operations | -30.22% | 0.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.22% | 0.97% | |||
| EBIT | -29.55% | 6.12% | |||
| EBITDA | -29.85% | 6.20% | |||
| EPS Basic | -29.80% | 1.36% | |||
| Normalized Basic EPS | -31.60% | 7.41% | |||
| EPS Diluted | -29.80% | 1.36% | |||
| Normalized Diluted EPS | -31.60% | 7.41% | |||
| Average Basic Shares Outstanding | 0.34% | 0.38% | |||
| Average Diluted Shares Outstanding | 0.34% | 0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||